Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Clinician Scientist - Phase 2

McGill University

$180,000.00

BRUISE CONTROL-2: A randomized controlled trial to investigate whether a strategy of Continued versus Interrupted Dabigatran at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events, leads to a reduction in the incidence of clinically significant hematoma

EF 2012-13

Résumé
Many patients requiring cardiac arrhythmia device surgery are on chronic blood thinners to prevent stroke. The management of blood thinners around the time of surgery presents a dilemma to physicians. Physicians usually discontinue long acting oral blood thinners (e.g. Coumadin) a few days before the surgery (for the effects of tablet blood thinners to be cleared) and then bridge with injection blood thinners (e.g. Heparin) before and after surgery for a few days while the restarted tablet blood thinner effect is building up to therapeutic levels. There are a number of downsides to bridging anti-coagulation including a substantial risk of significant device pocket hematoma (large collection of blood around the device battery). An alternative strategy of performing device surgery without stopping tablet blood thinners is currently being evaluated in the randomized controlled trial BRUISE CONTROL. Patients undergoing device surgery are randomly assigned to one of two treatment arms. In the conventional arm patents are bridged. In the experimental arm patients continue on tablet blood thinners. Recently, newer shorter acting tablet blood thinners (e.g. dabigatran) have been approved for use for stroke prevention. Given that their onset and offset of action is shorter than Coumadin, bridging anticoagulation with heparin is unlikely required for short periods of discontinuation around the time of device surgery. However, data is limited regarding the incidence of hematoma with peri-operative use of this medication. The important question of whether it safer to stop and restart dabigatran or to operate on continued dabigatran will be assessed in the current randomized controlled trial BRUISE CONTROL-2. Patients will be randomly assigned to either interrupted dabigatran or continued dabigatran at the time of device surgery. The primary outcome will be clinically significant hematoma.
Programme
CIHR Clinician Scientist - Phase 2
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
277865
Name
Essebag Vidal
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Clinician Scientist
Projecttitle
BRUISE CONTROL-2: A randomized controlled trial to investigate whether a strategy of Continued versus Interrupted Dabigatran at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events, leads to a reduction in the incidence of clinically significant hematoma
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$180,000
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 2
Keyworddelim
Anticoagulation; Atrial Fibrillaton; Dabigatran; Defibrillator; Hematoma; Pacemaker
Abstract
Many patients requiring cardiac arrhythmia device surgery are on chronic blood thinners to prevent stroke. The management of blood thinners around the time of surgery presents a dilemma to physicians. Physicians usually discontinue long acting oral blood thinners (e.g. Coumadin) a few days before the surgery (for the effects of tablet blood thinners to be cleared) and then bridge with injection blood thinners (e.g. Heparin) before and after surgery for a few days while the restarted tablet blood thinner effect is building up to therapeutic levels. There are a number of downsides to bridging anti-coagulation including a substantial risk of significant device pocket hematoma (large collection of blood around the device battery). An alternative strategy of performing device surgery without stopping tablet blood thinners is currently being evaluated in the randomized controlled trial BRUISE CONTROL. Patients undergoing device surgery are randomly assigned to one of two treatment arms. In the conventional arm patents are bridged. In the experimental arm patients continue on tablet blood thinners. Recently, newer shorter acting tablet blood thinners (e.g. dabigatran) have been approved for use for stroke prevention. Given that their onset and offset of action is shorter than Coumadin, bridging anticoagulation with heparin is unlikely required for short periods of discontinuation around the time of device surgery. However, data is limited regarding the incidence of hematoma with peri-operative use of this medication. The important question of whether it safer to stop and restart dabigatran or to operate on continued dabigatran will be assessed in the current randomized controlled trial BRUISE CONTROL-2. Patients will be randomly assigned to either interrupted dabigatran or continued dabigatran at the time of device surgery. The primary outcome will be clinically significant hematoma.
Competitiondate
201301
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Essebag, Vidal
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $180,000~ $0~